A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironmentsKevin C. Barry, Matthew F. Krummel, Amanda E. Nelson et al.|Nature Medicine|2018Cited by 1k
Discovering dominant tumor immune archetypes in a pan-cancer censusAlexis J. Combes, Sima P. Porten, Bushra Samad et al.|Cell|2021Cited by 172
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trialAmy S. Clark, Laura J. Esserman, Christina Yau et al.|Nature Communications|2021Cited by 73